Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Treatment of non-small cell lung carcinoma in early stages].
Meneses JC, Avila Martínez RJ, Ponce S, Zuluaga M, Bartolomé A, Gámez P. Meneses JC, et al. Among authors: ponce s. Cir Esp. 2013 Dec;91(10):625-32. doi: 10.1016/j.ciresp.2013.01.007. Epub 2013 Jul 3. Cir Esp. 2013. PMID: 23829961 Review. Spanish.
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Soria JC, et al. Among authors: ponce s. Lancet Oncol. 2015 Aug;16(8):990-8. doi: 10.1016/S1470-2045(15)00121-7. Epub 2015 Jul 6. Lancet Oncol. 2015. PMID: 26159065 Clinical Trial.
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K. Garon EB, et al. Among authors: ponce s. Clin Lung Cancer. 2017 Jan;18(1):96-99. doi: 10.1016/j.cllc.2016.05.023. Epub 2016 Jun 8. Clin Lung Cancer. 2017. PMID: 27894601 Clinical Trial.
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K. Reck M, et al. Among authors: ponce s. Clin Lung Cancer. 2018 May;19(3):213-220.e4. doi: 10.1016/j.cllc.2017.11.003. Epub 2017 Nov 21. Clin Lung Cancer. 2018. PMID: 29317191 Free article. Clinical Trial.
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M. Arriola E, et al. Among authors: ponce s. BMC Cancer. 2018 Jan 30;18(1):106. doi: 10.1186/s12885-018-4004-7. BMC Cancer. 2018. PMID: 29382302 Free PMC article.
Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).
Isla D, De Las Peñas R, Insa A, Marsé R, Martínez-Banaclocha N, Mut P, Morán T, Sala MÁ, Massuti B, Ortega AL, Jurado JM, Gómez-Codina J, Diz P, Artal Á, Gutiérrez V, Vázquez MF, Viñolas N, Maestu I, Camps C, Álvarez R, de Mon Soto MÁ, Ponce S, Provencio M. Isla D, et al. Among authors: ponce s. Lung Cancer. 2019 Sep;135:161-168. doi: 10.1016/j.lungcan.2018.11.041. Epub 2018 Dec 1. Lung Cancer. 2019. PMID: 31446990 Clinical Trial.
Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer.
Ciruelos EM, Díaz MN, Isla MD, López R, Bernabé R, González E, Cirauqui B, Coves J, Morales S, Arcediano A, Barneto I, Cerezuela P, Illarramendi JJ, Morales C, Ponce S. Ciruelos EM, et al. Among authors: ponce s. Eur J Cancer Care (Engl). 2019 Nov;28(6):e13164. doi: 10.1111/ecc.13164. Epub 2019 Sep 30. Eur J Cancer Care (Engl). 2019. PMID: 31571304
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Trigo J, et al. Among authors: ponce s. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. Lancet Oncol. 2020. PMID: 32224306 Clinical Trial.
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
Remon J, Nadal E, Dómine M, Ruffinelli J, García Y, Pardo JC, López R, Cilleruelo A, García-Campelo R, Martín P, Juan O, González-Larriba JL, Provencio M, Olmedo E, Ponce S, Cumplido D, Barenys C, Majem M, Massutti B, Rodriguez-Abreu D, Porta R, Sala MA, Martinez-Kareaga M, Lianes P, Reguart N. Remon J, et al. Among authors: ponce s. Lung Cancer. 2020 Sep;147:83-90. doi: 10.1016/j.lungcan.2020.06.034. Epub 2020 Jul 3. Lung Cancer. 2020. PMID: 32682189
279 results